Cargando…
Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA's benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937751/ https://www.ncbi.nlm.nih.gov/pubmed/36818742 http://dx.doi.org/10.1155/2023/7301284 |
_version_ | 1784890491801698304 |
---|---|
author | Williams, Andrew Elbakry, Amr A. Trump, Tyler Prisneac, Ion Smolkin, Matthew Zekan, David Salkini, Mohamad W. |
author_facet | Williams, Andrew Elbakry, Amr A. Trump, Tyler Prisneac, Ion Smolkin, Matthew Zekan, David Salkini, Mohamad W. |
author_sort | Williams, Andrew |
collection | PubMed |
description | Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA's benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-specific membrane antigen positron emission tomography (PSMA PET) can help localize the location of recurrences for better excision and management. Here, we present a 55-year-old with prostate cancer, with initially undetectable postprostatectomy PSA levels, who later presented with a PSA of 3.47 ng/mL. PSMA PET showed isolated uptake in an abdominal wall mass. Pelvic lymphadenectomy and abdominal wall mass excision were performed, confirming a single metastasis in an abdominal wall lymph node. Metastasectomy led to a dramatic drop in PSA to 0.10 ng/mL both postoperatively and on long-term follow-up. Our case illustrates the potential benefit of metastasis-directed therapy in delayed oligometastasis following definitive management of prostate cancer. |
format | Online Article Text |
id | pubmed-9937751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-99377512023-02-18 Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy Williams, Andrew Elbakry, Amr A. Trump, Tyler Prisneac, Ion Smolkin, Matthew Zekan, David Salkini, Mohamad W. Case Rep Urol Case Report Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA's benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-specific membrane antigen positron emission tomography (PSMA PET) can help localize the location of recurrences for better excision and management. Here, we present a 55-year-old with prostate cancer, with initially undetectable postprostatectomy PSA levels, who later presented with a PSA of 3.47 ng/mL. PSMA PET showed isolated uptake in an abdominal wall mass. Pelvic lymphadenectomy and abdominal wall mass excision were performed, confirming a single metastasis in an abdominal wall lymph node. Metastasectomy led to a dramatic drop in PSA to 0.10 ng/mL both postoperatively and on long-term follow-up. Our case illustrates the potential benefit of metastasis-directed therapy in delayed oligometastasis following definitive management of prostate cancer. Hindawi 2023-02-10 /pmc/articles/PMC9937751/ /pubmed/36818742 http://dx.doi.org/10.1155/2023/7301284 Text en Copyright © 2023 Andrew Williams et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Williams, Andrew Elbakry, Amr A. Trump, Tyler Prisneac, Ion Smolkin, Matthew Zekan, David Salkini, Mohamad W. Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy |
title | Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy |
title_full | Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy |
title_fullStr | Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy |
title_full_unstemmed | Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy |
title_short | Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy |
title_sort | solitary abdominal wall lymph node recurrence in prostate cancer patient with dramatic prostate-specific antigen decrease following metastasectomy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937751/ https://www.ncbi.nlm.nih.gov/pubmed/36818742 http://dx.doi.org/10.1155/2023/7301284 |
work_keys_str_mv | AT williamsandrew solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy AT elbakryamra solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy AT trumptyler solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy AT prisneacion solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy AT smolkinmatthew solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy AT zekandavid solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy AT salkinimohamadw solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy |